The FDA approved the first drug for the rare disease Friedreich’s ataxia; House Republicans seek information from pharmacy benefit managers (PBMs); FDA panel narrowly supports respiratory syncytial virus (RSV) vaccine for older adults.
Rare Disease Drug for Friedreich’s Ataxia Approved
The FDA approved Reata Pharmaceuticals’ rare disease drug, omaveloxolone (Skyclarys), the first approved treatment for the rare genetic disorder Friedreich’s ataxia, which causes progressive nervous system damage and can lead to early death. The drug is the firm’s first approved therapy, according to Reuters.
Congress Drug-Price Investigation Focuses on Pharmacy Benefit Managers
An investigation into companies that manage drug benefits has been initiated by House Republicans, increasing the attention placed on pharmacy benefit managers (PBMs) who play a role in medication costs, reported The Wall Street Journal. The House Oversight and Accountability Committee said that it sent letters to the largest PBMs, consisting of CVS Health Corp.’s CVS Caremark, Cigna Group’s Express Scripts, and UnitedHealth Group Inc.’s OptumRx, looking for documents about their negotiated drug-price rebates and fees they charge.
FDA Panel Just Barely Backs Pfizer RSV Vaccine
An FDA advisory panel narrowly supported an experimental Pfizer vaccine for respiratory syncytial virus (RSV), voting 7-4 on 2 separate questions regarding Pfizer’s safety and efficacy data for people aged 60 and older, reported The Associated Press. One of the panelists abstained from voting. The recommendation is not binding, and the FDA will make a decision on the vaccine in the coming months. The favorable vote came in spite of concerns about possible rare reactions and questions about how the vaccine affected people who have the greatest risks from RSV.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More